Clinical Trials

Multiple late-stage Phase 3 clinical trials sponsored by Merck Sharp & Dohme LLC have completed recruitment evaluating sugammadex in general anesthesia settings. These studies investigated the agent's efficacy, safety, and pharmacokinetic profile for reversing neuromuscular blockade, including comparative evaluations and assessments in subjects with normal or impaired renal function. Overall, these clinical investigations emphasize the therapeutic focus on optimizing recovery from neuromuscular blockade in surgical patients.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00451100 Completed
Anesthesia General
Merck Sharp & Dohme LLC
2005-11-10 Phase 3
NCT00482599 Completed
Anesthesia General
Merck Sharp & Dohme LLC
2005-06-01 Phase 3

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Sugammadex (sodium) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Sugammadex operates as a modified gamma-cyclodextrin selective relaxant binding agent that encapsulates lipophilic aminosteroidal neuromuscular blocking agents, such as rocuronium and vecuronium, with high affinity in plasma. By forming a stable guest-host complex, it rapidly decreases the concentration of free neuromuscular blocker at the neuromuscular junction, thereby restoring skeletal muscle function and effectively reversing neuromuscular blockade during general anesthesia.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.